NeoGenomics Inc. (NASDAQ: NEO) raised its fiscal year 2026 revenue guidance on Thursday, projecting sales between $802.000 million and $806.000 million. The company previously forecasted a range of $797.000 million to $803.000 million for the period. This adjustment places the midpoint of the new guidance above the Wall Street consensus estimate of $800.433 million, indicating stronger-than-expected performance in its core diagnostic testing segments.

The revision reflects improved operational visibility and sustained demand across NeoGenomics’ laboratory network. By lifting both the floor and ceiling of its guidance range, management signals confidence in maintaining growth trajectories despite broader macroeconomic uncertainties affecting the healthcare sector. The updated outlook suggests that recent quarters have likely trended toward the higher end of prior expectations, prompting this proactive adjustment to align investor expectations with current business fundamentals.

Guidance Revision Details

The following table outlines the changes in NeoGenomics’ fiscal year 2026 financial outlook:

The lower bound of the guidance increased by $5.000 million, while the upper bound rose by $3.000 million. This narrowing of the gap between the previous low end and the current high end highlights a consolidation of expectations around higher revenue levels. The new range entirely exceeds the prior ceiling at its midpoint, reinforcing the positive shift in sentiment.

What the Numbers Show

The decision to raise guidance above the consensus estimate of $800.433 million is a significant signal of operational strength. Typically, companies provide conservative estimates to manage downside risk; exceeding these expectations proactively suggests that NeoGenomics is capturing market share or experiencing volume growth that outpaces industry averages. The fact that the entire new range sits near or above the analyst estimate implies that the company’s internal models are now more optimistic than external analysts, potentially setting the stage for further upside surprises in subsequent quarterly reports if execution remains consistent.

NeoGenomics, Inc. has finalized a civil settlement with the Department of Justice (DOJ) regarding an investigation into consulting services provided to healthcare providers. The settlement resolves issues related to the company's Laboratory Collaboration Initiative program, which involved laboratory testing services. NeoGenomics self-disclosed the matter to the Office of Inspector General of the U.S. Department of Health and Human Services (OIG) in November 2021 and cooperated with the government's investigation.

The company has agreed to pay $9,813,260 plus interest at a rate of 4.250% per annum from January 16, 2026, to the United States. NeoGenomics previously disclosed in its SEC filings that it had accrued a reserve of $11.2 million to cover potential damages and liabilities associated with the investigation. The settlement agreement does not constitute an admission of liability by the company or a concession by the United States that its claims are not well founded.

Tony Zook, Chief Executive Officer, stated that the resolution of this voluntary disclosure allows the company to continue moving forward with its vision for personalized cancer care. The settlement concludes a legacy matter for the oncology diagnostic solutions provider.

Financial Impact of Settlement

The following table outlines the financial details of the settlement agreement:

Background and Cooperation

The investigation focused on consulting services provided by NeoGenomics to certain healthcare providers for laboratory testing services. The DOJ acknowledged the company's cooperation throughout the government's investigation. The Laboratory Collaboration Initiative program was the specific area under scrutiny. NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories in the US and a CAP-accredited laboratory in the United Kingdom.